CryoPort (NASDAQ:CYRX) Stock Crosses Above 200-Day Moving Average – Should You Sell?

CryoPort, Inc. (NASDAQ:CYRX)’s share price crossed above its two hundred day moving average during trading on Monday . The stock has a two hundred day moving average of $6.65 and traded as high as $7.72. CryoPort shares last traded at $7.50, with a volume of 328,354 shares traded.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on CYRX. BTIG Research decreased their target price on CryoPort from $13.00 to $10.00 and set a “buy” rating for the company in a report on Monday, July 7th. Guggenheim reiterated a “buy” rating and issued a $10.00 price objective on shares of CryoPort in a research note on Wednesday, April 16th. UBS Group upped their target price on shares of CryoPort from $10.00 to $11.00 and gave the stock a “buy” rating in a research note on Tuesday, April 1st. Morgan Stanley decreased their price target on shares of CryoPort from $8.00 to $7.00 and set an “equal weight” rating for the company in a research note on Monday, May 5th. Finally, Roth Mkm reiterated a “buy” rating and set a $15.00 price target on shares of CryoPort in a report on Tuesday, April 1st. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $10.88.

CryoPort Price Performance

The company has a debt-to-equity ratio of 0.51, a current ratio of 5.56 and a quick ratio of 5.24. The company’s 50 day simple moving average is $6.73 and its 200 day simple moving average is $6.65. The company has a market capitalization of $376.05 million, a PE ratio of -3.21 and a beta of 1.89.

CryoPort (NASDAQ:CYRX) last issued its earnings results on Wednesday, May 7th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.23) by $0.01. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. The business had revenue of $41.04 million during the quarter, compared to analysts’ expectations of $56.19 million. As a group, sell-side analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Insider Transactions at CryoPort

In other news, Director Ramkumar Mandalam sold 13,321 shares of the business’s stock in a transaction dated Tuesday, June 24th. The stock was sold at an average price of $7.01, for a total value of $93,380.21. Following the completion of the sale, the director directly owned 73,056 shares of the company’s stock, valued at approximately $512,122.56. The trade was a 15.42% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Jerrell Shelton sold 151,304 shares of the firm’s stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $6.81, for a total value of $1,030,380.24. Following the transaction, the chief executive officer owned 912,419 shares in the company, valued at $6,213,573.39. This represents a 14.22% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 449,719 shares of company stock worth $3,042,327. 10.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On CryoPort

Hedge funds have recently modified their holdings of the business. Point72 Asia Singapore Pte. Ltd. boosted its stake in CryoPort by 148.7% during the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company’s stock worth $28,000 after purchasing an additional 2,120 shares during the period. Lazard Asset Management LLC purchased a new stake in shares of CryoPort in the fourth quarter valued at about $51,000. Quarry LP purchased a new stake in shares of CryoPort in the fourth quarter valued at about $69,000. Avanza Fonder AB boosted its stake in shares of CryoPort by 31.4% during the second quarter. Avanza Fonder AB now owns 10,882 shares of the company’s stock worth $81,000 after buying an additional 2,601 shares during the period. Finally, SBI Securities Co. Ltd. grew its holdings in shares of CryoPort by 548,750.0% during the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company’s stock worth $67,000 after buying an additional 10,975 shares during the last quarter. 92.90% of the stock is currently owned by hedge funds and other institutional investors.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.